This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Botanix Pharmaceuticals Limited
Drug Names(s): BTX1308, BTX 1308
Description: BTX1308 contains cannabidiol as an active ingredient. BTX1308 has anti-inflammatory and anti-bacterial properties and reduces keratinocyte proliferation.
Deal Structure: In March 2013, Bone Medical announced it has signed an agreement to acquire Botanix Pharmaceuticals, Inc. In June 2016, Bone Medical announced that the Prospectus Offer for the acquisition of Botanix Pharmaceuticals has closed and a shareholder meeting was held where existing shareholders approved the acquisition of Botanix Pharmaceuticals, including the resolution to change the name of the company to Botanix Pharmaceuticals Limited.
Additional information available to subscribers only: